Newly Diagnosed With Laryngeal Cancer: First Steps

This page is for people just diagnosed with laryngeal (voice box) cancer and the people helping them. It covers where in the larynx the tumor is, how staging works, what the main voice-preservation trial found, and questions to ask early on.

The larynx has three levels, and the level where the tumor sits affects how it behaves and how it is treated.

Glottis. The true vocal cords. NCI notes something unusual about them: they have no lymphatics, the small vessels that drain fluid to lymph nodes. Cancer confined to the cords rarely spreads to lymph nodes. Early vocal cord cancers are usually found because of hoarseness.

Supraglottis. The area above the cords. It is rich in lymphatic drainage. Between 25 and 50 percent of patients already have involved lymph nodes at diagnosis, depending on stage. NCI lists sore throat, painful swallowing, referred ear pain, a change in voice quality, and enlarged neck nodes. These figures come from the National Cancer Institute’s “Laryngeal (Voice Box) Cancer.”

Subglottis. Below the cords, and rare. Drainage runs to the pretracheal, paratracheal, and inferior jugular nodes. It sometimes reaches nodes in the chest.

Ask which subsite is named in your report. A T1 glottic cancer and a T1 supraglottic cancer are treated as different problems.

For 2026 the American Cancer Society puts the United States total at 12,290 new cases and 3,960 deaths. Cure rates for small node-negative tumors run 75 to 95 percent. The range depends on site, tumor bulk, and how deeply the cancer has spread into tissue.

NCI is unusually direct about tobacco and alcohol during treatment. Patients who keep smoking and drinking through treatment have lower cure rates. They also face a higher risk of second primary tumors.

The patient version puts it in one sentence: smoking tobacco and drinking alcohol decrease the effectiveness of treatment for laryngeal cancer.

NCI also notes that many patients here die of another illness rather than the cancer. It ties this to health problems from smoking and alcohol use.

Ask your team about a stop-smoking program at the same visit where you discuss treatment. NCI says continued smoking and drinking make treatment less effective.

Staging here is done largely by looking, not by measuring.

The workup uses inspection and palpation, which means feeling the neck by hand. It also uses fiberoptic laryngoscopy, which passes a flexible scope through the nose to view the larynx. Panendoscopy, a scope exam of the throat and nearby areas done under anesthesia, shows how far the disease reaches locally. MRI, CT, or PET-CT is added before treatment starts.

The findings that move the T stage are specific:

• Vocal cord mobility. Preserved movement means a lower T stage. A fixed cord indicates T3.
• Cartilage. Invasion all the way through the thyroid cartilage means T4a.
• Extension outside the larynx, into the trachea, esophagus, or soft tissues, also means T4a.
• T4b is the most advanced. It means invasion of the prevertebral space, a carotid artery wrapped by tumor, or spread into the chest.

One more number matters before treatment. NCI reports higher local control and survival in patients whose hemoglobin was above 13 g/dL before radiation. Ask what yours is.

The question most people want answered is whether the voice box can be saved. RTOG 91-11 is the trial that answers it.

It randomized 547 patients with locally advanced laryngeal cancer. There were three nonsurgical arms, and median follow-up ran 10.8 years:

1. Chemotherapy first, using cisplatin and fluorouracil, then radiation.
2. Concurrent chemoradiation, with cisplatin given alongside radiation.
3. Radiation alone.

The results at 10 years:

• Larynx kept intact: 81.7 percent with concurrent chemoradiation, 67.5 percent with chemotherapy first, 63.8 percent with radiation alone.
• Local and regional failure: concurrent chemotherapy cut the risk by 41 percent compared with radiation alone.
• Severe late toxicity, graded 3 through 5, hit 33.3 percent with concurrent chemotherapy. It hit 30.6 percent with chemotherapy first, and 38 percent with radiation alone. The differences were not statistically significant.
• Overall survival was 55 percent at 5 years with concurrent chemotherapy. There was no significant difference between the three arms.

These figures are also from the National Cancer Institute’s “Laryngeal (Voice Box) Cancer.”

Read those last two lines carefully. Concurrent chemoradiation preserved the most larynxes. It did not extend life compared with the other arms. About a third of patients in every arm had severe late toxicity. So this is a quality-of-life decision with real numbers behind it. It is not a survival gamble.

Stages I and II. Radiation therapy or surgery.

Stages III and IV. Combined treatment. Concurrent chemoradiation is used to try to keep the larynx in suitable candidates. Total laryngectomy is an option for T4 disease.

Total laryngectomy removes the whole voice box. NCI describes the result plainly. A hole is made in the front of the neck so the patient can breathe. This is called a tracheostomy. Ask your team how it will change breathing and speaking.

DPYD genotyping, if fluorouracil is in your plan. About 1 to 2 percent of people carry pathogenic variants in the DPYD gene. NCI states that people with the DPYD*2A variant who get fluoropyrimidines such as fluorouracil may have severe, life-threatening side effects, sometimes fatal. The test costs under $200, though NCI notes it can delay therapy by about 2 weeks.

A dental evaluation. NCI advises that treatment be discussed in a multidisciplinary consultation, including dental and oral surgery, before it is prescribed. Ask whether a dental visit should happen before radiation.

Your thyroid. An underactive thyroid affects 30 to 40 percent of patients who get external-beam radiation near the thyroid. Prospective data showed a 55.1 percent rate at a median of 41 months. Of those cases, 39.3 percent were subclinical. That means blood tests caught them before symptoms appeared. NCI says thyroid function testing is a consideration before treatment and in follow-up.

Second cancers. Second primary tumors have been reported in as many as 25 percent of patients whose original tumor was controlled. NCI says they are often in the aerodigestive tract, meaning the mouth, throat, airway, and food pipe.

Timing of recurrence. Risk is highest in the first 2 to 3 years. NCI notes that recurrences after 5 years are rare and usually represent new primary cancers.

• Which subsite is this: glottis, supraglottis, or subglottis?
• Is vocal cord mobility preserved, and is there cartilage invasion?
• What is my pretreatment hemoglobin?
• Am I a candidate for larynx preservation, and what is the salvage plan if it fails?
• If I need fluorouracil, will DPYD testing be done first?
• Has a dental evaluation been scheduled before radiation?
• Who will follow my thyroid function, and starting when?
• Can I be referred to a speech-language pathologist before treatment, not after?

The larynx is the airway. That is why breathing symptoms here are treated differently from breathing symptoms elsewhere.

• Call 911 or go to an emergency department if you are gasping, choking, or too short of breath to finish a sentence. Noisy or crowing breathing at rest belongs in the same group. Do not drive yourself.
• Call your care team the same day if you are more breathless than usual, you cough up blood, or food and drink keep going down the wrong way and setting off a coughing fit.
• Call your care team within a day or two if swallowing has become painful enough that you are skipping meals, or a neck lump is clearly enlarging while you wait for treatment to be scheduled.

• https://www.cancer.gov/types/head-and-neck/hp/adult/laryngeal-treatment-pdq
• https://www.cancer.gov/types/head-and-neck/patient/adult/laryngeal-treatment-pdq
• https://www.cancer.org/cancer/types/laryngeal-and-hypopharyngeal-cancer/about/key-statistics.html